Genelux (GNLX) Competitors

Genelux logo
$1.92 +0.06 (+2.95%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$1.82 -0.10 (-5.42%)
As of 11/16/2026 07:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GNLX vs. EDIT, EIKN, ALT, BNTC, and LRMR

Should you buy Genelux stock or one of its competitors? Genelux's main competitors and comparable companies include Editas Medicine (EDIT), Eikon Therapeutics (EIKN), Altimmune (ALT), Benitec Biopharma (BNTC), and Larimar Therapeutics (LRMR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Genelux compare to Editas Medicine?

Genelux (NASDAQ:GNLX) and Editas Medicine (NASDAQ:EDIT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

37.3% of Genelux shares are held by institutional investors. Comparatively, 71.9% of Editas Medicine shares are held by institutional investors. 7.5% of Genelux shares are held by insiders. Comparatively, 3.1% of Editas Medicine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Genelux has a net margin of 0.00% compared to Editas Medicine's net margin of -144.95%. Editas Medicine's return on equity of -130.43% beat Genelux's return on equity.

Company Net Margins Return on Equity Return on Assets
GeneluxN/A -205.85% -138.79%
Editas Medicine -144.95%-130.43%-36.45%

Genelux has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market.

Genelux presently has a consensus price target of $20.00, suggesting a potential upside of 941.67%. Editas Medicine has a consensus price target of $5.83, suggesting a potential upside of 211.94%. Given Genelux's stronger consensus rating and higher possible upside, equities analysts clearly believe Genelux is more favorable than Editas Medicine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genelux
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75
Editas Medicine
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71

Genelux has higher earnings, but lower revenue than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genelux$10K8,686.08-$32.15M-$0.86N/A
Editas Medicine$40.52M7.12-$160.06M-$0.62N/A

In the previous week, Editas Medicine had 9 more articles in the media than Genelux. MarketBeat recorded 13 mentions for Editas Medicine and 4 mentions for Genelux. Genelux's average media sentiment score of 1.82 beat Editas Medicine's score of 0.29 indicating that Genelux is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Genelux
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Editas Medicine
4 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Genelux and Editas Medicine tied by winning 8 of the 16 factors compared between the two stocks.

How does Genelux compare to Eikon Therapeutics?

Genelux (NASDAQ:GNLX) and Eikon Therapeutics (NASDAQ:EIKN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Genelux presently has a consensus price target of $20.00, suggesting a potential upside of 941.67%. Eikon Therapeutics has a consensus price target of $24.67, suggesting a potential upside of 357.64%. Given Genelux's stronger consensus rating and higher possible upside, equities research analysts clearly believe Genelux is more favorable than Eikon Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genelux
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75
Eikon Therapeutics
2 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.56

Genelux has higher revenue and earnings than Eikon Therapeutics. Genelux is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genelux$10K8,686.08-$32.15M-$0.86N/A
Eikon TherapeuticsN/AN/A-$324.25M-$4.09N/A

Eikon Therapeutics' return on equity of 0.00% beat Genelux's return on equity.

Company Net Margins Return on Equity Return on Assets
GeneluxN/A -205.85% -138.79%
Eikon Therapeutics N/A N/A N/A

In the previous week, Eikon Therapeutics had 8 more articles in the media than Genelux. MarketBeat recorded 12 mentions for Eikon Therapeutics and 4 mentions for Genelux. Genelux's average media sentiment score of 1.82 beat Eikon Therapeutics' score of 0.90 indicating that Genelux is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Genelux
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Eikon Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

37.3% of Genelux shares are owned by institutional investors. 7.5% of Genelux shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Genelux beats Eikon Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Genelux compare to Altimmune?

Genelux (NASDAQ:GNLX) and Altimmune (NASDAQ:ALT) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

Genelux has higher earnings, but lower revenue than Altimmune. Genelux is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genelux$10K8,686.08-$32.15M-$0.86N/A
Altimmune$40K7,586.28-$88.09M-$0.72N/A

In the previous week, Altimmune had 22 more articles in the media than Genelux. MarketBeat recorded 26 mentions for Altimmune and 4 mentions for Genelux. Genelux's average media sentiment score of 1.82 beat Altimmune's score of 0.49 indicating that Genelux is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Genelux
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Altimmune
7 Very Positive mention(s)
3 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

37.3% of Genelux shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 7.5% of Genelux shares are owned by insiders. Comparatively, 1.6% of Altimmune shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Genelux has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, Altimmune has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market.

Genelux presently has a consensus price target of $20.00, suggesting a potential upside of 941.67%. Altimmune has a consensus price target of $14.33, suggesting a potential upside of 818.80%. Given Genelux's stronger consensus rating and higher probable upside, research analysts plainly believe Genelux is more favorable than Altimmune.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genelux
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75
Altimmune
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.70

Altimmune's return on equity of -31.84% beat Genelux's return on equity.

Company Net Margins Return on Equity Return on Assets
GeneluxN/A -205.85% -138.79%
Altimmune N/A -31.84%-27.40%

Summary

Genelux and Altimmune tied by winning 8 of the 16 factors compared between the two stocks.

How does Genelux compare to Benitec Biopharma?

Genelux (NASDAQ:GNLX) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Benitec Biopharma's return on equity of -28.41% beat Genelux's return on equity.

Company Net Margins Return on Equity Return on Assets
GeneluxN/A -205.85% -138.79%
Benitec Biopharma N/A -28.41%-27.76%

In the previous week, Benitec Biopharma had 9 more articles in the media than Genelux. MarketBeat recorded 13 mentions for Benitec Biopharma and 4 mentions for Genelux. Genelux's average media sentiment score of 1.82 beat Benitec Biopharma's score of 0.67 indicating that Genelux is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Genelux
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Benitec Biopharma
1 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

37.3% of Genelux shares are held by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are held by institutional investors. 7.5% of Genelux shares are held by company insiders. Comparatively, 8.0% of Benitec Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Genelux has higher revenue and earnings than Benitec Biopharma. Benitec Biopharma is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genelux$10K8,686.08-$32.15M-$0.86N/A
Benitec BiopharmaN/AN/A-$45.55M-$0.98N/A

Genelux has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market.

Genelux presently has a consensus target price of $20.00, indicating a potential upside of 941.67%. Benitec Biopharma has a consensus target price of $21.85, indicating a potential upside of 155.90%. Given Genelux's stronger consensus rating and higher probable upside, research analysts clearly believe Genelux is more favorable than Benitec Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genelux
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75
Benitec Biopharma
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.70

Summary

Genelux beats Benitec Biopharma on 9 of the 15 factors compared between the two stocks.

How does Genelux compare to Larimar Therapeutics?

Genelux (NASDAQ:GNLX) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Genelux has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, Larimar Therapeutics has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market.

Genelux has higher revenue and earnings than Larimar Therapeutics. Genelux is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genelux$10K8,686.08-$32.15M-$0.86N/A
Larimar TherapeuticsN/AN/A-$165.67M-$1.95N/A

Genelux currently has a consensus target price of $20.00, suggesting a potential upside of 941.67%. Larimar Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 233.33%. Given Genelux's higher possible upside, equities research analysts clearly believe Genelux is more favorable than Larimar Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genelux
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75
Larimar Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
3.00

Larimar Therapeutics' return on equity of -137.39% beat Genelux's return on equity.

Company Net Margins Return on Equity Return on Assets
GeneluxN/A -205.85% -138.79%
Larimar Therapeutics N/A -137.39%-97.65%

In the previous week, Larimar Therapeutics had 23 more articles in the media than Genelux. MarketBeat recorded 27 mentions for Larimar Therapeutics and 4 mentions for Genelux. Genelux's average media sentiment score of 1.82 beat Larimar Therapeutics' score of 1.11 indicating that Genelux is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Genelux
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Larimar Therapeutics
11 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

37.3% of Genelux shares are held by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are held by institutional investors. 7.5% of Genelux shares are held by company insiders. Comparatively, 4.0% of Larimar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Larimar Therapeutics beats Genelux on 9 of the 15 factors compared between the two stocks.

Get Genelux News Delivered to You Automatically

Sign up to receive the latest news and ratings for GNLX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GNLX vs. The Competition

MetricGeneluxBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$85.97M$4.15B$7.83B$12.17B
Dividend YieldN/A3.62%2.46%4.42%
P/E Ratio-2.2328.3833.7827.89
Price / Sales8,686.0816.048.585.72
Price / CashN/A26.3721.9322.50
Price / Book6.404.074.403.70
Net Income-$32.15M-$22.86M$3.52B$392.17M
7 Day Performance-1.54%-6.15%-4.48%-3.37%
1 Month Performance-20.66%-4.92%-3.53%-5.82%
1 Year Performance-63.43%-3.09%0.12%-6.24%

Genelux Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GNLX
Genelux
3.1844 of 5 stars
$1.92
+2.9%
$20.00
+941.7%
-63.9%$85.97M$10KN/A26
EDIT
Editas Medicine
2.1531 of 5 stars
$2.19
+2.1%
$5.83
+167.0%
-28.1%$337.23M$40.52MN/A87
EIKN
Eikon Therapeutics
3.3609 of 5 stars
$5.98
-1.1%
$24.67
+312.8%
N/A$323.67MN/AN/A384
ALT
Altimmune
3.9706 of 5 stars
$1.66
+2.8%
$14.33
+766.1%
-62.6%$321.93M$40KN/A57
BNTC
Benitec Biopharma
2.0259 of 5 stars
$9.09
+0.0%
$22.00
+141.9%
-35.1%$317.29MN/AN/A24

Related Companies and Tools


This page (NASDAQ:GNLX) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners